Philippines Moves Toward Slapping Price Caps On Innovative Drugs
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Multinational pharmaceutical companies in the Philippines are expected to submit a plan Saturday "voluntarily" lowering prices for at least 22 essential drugs by half or more in a bid to avert a law mandating them to do so
You may also be interested in...
Coalition Blames Slow Judicial Process and Parallel Drug Importation Program For Fake Drugs In Philippines
SHANGHAI - The Coalition Against Fake Medicines, a group of multisectoral representatives in the healthcare industry, including pharmacists, retailers, and generics companies in the Philippines, recently called the country's slow judicial process a major factor in the rise of fake medicines, and said the government's parallel drug importation program under the Cheap Medicine Act partly helps counterfeits enter the country
Coalition Blames Slow Judicial Process and Parallel Drug Importation Program For Fake Drugs In Philippines
SHANGHAI - The Coalition Against Fake Medicines, a group of multisectoral representatives in the healthcare industry, including pharmacists, retailers, and generics companies in the Philippines, recently called the country's slow judicial process a major factor in the rise of fake medicines, and said the government's parallel drug importation program under the Cheap Medicine Act partly helps counterfeits enter the country
Pfizer, Unilab Prepare For Battle Over Lipitor Patent In The Philippines
SHANGHAI - After patent infringement disputes between Pfizer and Philippines-based generic drug manufacturer United Laboratories (Unilab) over Pfizer's Lipitor patent, a Makati court is expected to decide in January whether Unilab can continue selling its version of Pfizer's anti-cholesterol statin branded as Avamax. The two companies start presenting evidence this month